Japanese company’s £46bn deal for Shire
Japanese drugs firm Takeda has won shareholder approval for its £46bn acquisition of Shire, paving the way for the deal to create one of the biggest pharmaceutical firms in the world.
Takeda said it won support from at least 88 per cent of its shareholders at an extraordinary general meeting in Osaka on Wednesday.
Shire investors also overwhelmingly gave the deal the thumbs up, with 99.8 per cent of investors voting in favour, which means the deal is now expected to complete on January 8.
Christophe Weber, Takeda’s president and chief executive, said: “With shareholder approval secured, we are looking forward to closing the acquisition in the coming weeks to create a more competitive, agile, highly profitable, and therefore more resilient company, poised to deliver highly innovative medicines and transformative care to patients around the world.”
Shares in Shire, which have soared since the deal was announced, rose another 3 per cent on news of the shareholder approval.
Takeda reached a deal in May to buy Irish rival Shire for £49.01 a share.
But there had been concerns the company is taking on too much debt to finance the deal.